Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia

INTRODUCTION: The advent of new disease-modifying therapies (DMTs), such as monoclonal antibodies (mAbs), resulted in significant changes in the treatment guidelines for Multiple sclerosis (MS) and improvement in the clinical outcomes. However, mAbs, such as rituximab, natalizumab, and ocrelizumab,...

Descripción completa

Detalles Bibliográficos
Autores principales: Alharbi, Mansour A., Aldosari, Fahad, Althobaiti, Ahmed Hasan, Abdullah, Faris M., Aljarallah, Salman, Alkhawajah, Nuha M., Alanazi, Miteb, AlRuthia, Yazed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223862/
https://www.ncbi.nlm.nih.gov/pubmed/37237257
http://dx.doi.org/10.1186/s12913-023-09462-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223862/
https://www.ncbi.nlm.nih.gov/pubmed/37237257
http://dx.doi.org/10.1186/s12913-023-09462-z

Ejemplares similares